

Claim 148: An isolated nucleic acid molecule consisting of a nucleotide sequence as set forth in SEQ ID NO: 9, 10, 11, 12, 13, or 14.

Claim 149: Kit useful in determining expression of a cancer associated antigen, comprising (i) nucleic acid molecules consisting of the nucleotide sequences set forth in SEQ ID NOS: 9 and 10, (ii) nucleic acid molecules consisting of the nucleotide sequences set forth in SEQ ID NOS: 11 and 12, and (iii) nucleic acid molecules consisting of the nucleotide sequences set forth in SEQ ID NOS: 13 and 14, wherein (i), (ii) and (iii) are presented in separate container means in said kit.

Claim 150: A composition comprising a expression vector, wherein said expression vector encodes one or more peptides, wherein each of said peptides consists of 8 to 25 amino acids, wherein said 8 to 25 amino acids are present in consecutive order in the protein encoded by the isolated nucleic acid molecule of claim 110, and a pharmaceutically acceptable carrier.

Claim 151: The composition of claim 150, wherein said expression vector encodes a plurality of peptides.

REMARKS

Applicants wish to express their appreciation to Examiner Canella, for the courtesies extended during the telephone interview of January 31, 2003.

In the office action of November 20, 2002, claims 108, 126, 129, 130, 143 & 144 were rejected. Claims 134 and 141 were objected to.

Claims 148 & 149 replace claims 108 & 129, and present changes which the examiner agreed to during the telephone interview. Similarly, claims 150 & 151 replace claims 143 & 144, and also incorporate the language which the examiner indicated was fine.

Claims 126, 130, 134 & 141 have not been replaced.